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Background: Enhanced recovery after surgery (ERAS) programs have been reported to be feasible and useful for
maintaining physiological function and facilitating recovery after colorectal surgery. The feasibility of such programs
in gastric surgery remains unclear. This study assessed whether an ERAS program is feasible in patients who
undergo gastric surgery.
Methods: The subjects were patients who underwent gastric surgery between June 2009 and February 2011 at the
Department of Gastrointestinal Surgery, Kanagawa Cancer Center. They received perioperative care according to an
ERAS program. All data were retrieved retrospectively. The primary end point was the incidence of postoperative
complications. The secondary end point was postoperative outcomes.
Results: A total of 203 patients were studied. According to the Clavien-Dindo classification, the incidence of ≥ grade
2 postoperative complications was 10.8% and that of ≥ grade 3 complications was 3.9%. Nearly all patients did not
require delay of meal step-up (95.1%). Only 6 patients (3.0%) underwent reoperation. The median postoperative
hospital stay was 9 days. Only 4 patients (2.0%) required readmission. There was no mortality.
Conclusions: Our results suggest that our ERAS program is feasible in patients who undergo gastric surgery.
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Gastric cancer is the second leading cause of cancer-
related death worldwide [1]. Complete surgical resection
plays the most important role in the cure of gastric can-
cer; however, surgery for gastric cancer remains a high-
risk procedure with clinically significant postoperative
stress, complications, and sequelae. Morbidity and mor-
tality from radical gastrectomy range from 9.1-46.0%
and 0-13%, respectively [2-7].
Enhanced recovery after surgery (ERAS) programs have
been proposed to maintain physiological function and fa-
cilitate postoperative recovery [8]. In the following studies,
ERAS was considered to reduce rates of morbidity, shorten
length of hospital stay [9-11]. ERAS programs have many
elements, including preoperative education, preoperative
carbohydrate loading, omission of bowel preparation,* Correspondence: takay0218@yahoo.co.jp
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unless otherwise stated.epidural analgesia without opioids, early postoperative
enteral feeding, early mobilization of patients, and throm-
botic prophylaxis. In colorectal surgery, several studies have
reported that ERAS programs are feasible and useful [9-11].
We previously demonstrated that an ERAS protocol is
useful in patients who undergo elective radical gastrectomy
[12]. Other studies have reported that ERAS programs or
fast-track surgery in gastric surgery can accelerate postop-
erative rehabilitation [13-18]. However, the number of pa-
tients assessed in these studies was small. In addition,
some studies found that the incidence of some postopera-
tive complications, especially nausea, vomiting, and post-
operative ileus, tended to be higher in the ERAS group
than in the conventional group, suggesting that ERAS pro-
grams might increase the risk of some complications after
gastric surgery. Because of these controversial results, it is
necessary to confirm the feasibility of ERAS programs in
gastric surgery.
The present study evaluated whether an ERAS program
was feasible in more than 200 patients who underwentl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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gastrointestinal complications.Methods
Patients
Between June 2009 and February 2011, a total of 256 pa-
tients with gastric cancer underwent surgery at the De-
partment of Gastrointestinal Surgery, Kanagawa Cancer
Center. The inclusion criteria for this study were (1) a
histologically confirmed diagnosis of adenocarcinoma of
stomach and (2) the receipt of elective distal gastrec-
tomy or total gastrectomy with lymphadenectomy. We
excluded patients who preoperatively received any chemo-
therapy or radiotherapy. We also excluded patients who
underwent proximal gastrectomy or laparoscopy-assisted
total gastrectomy because these procedures are not stand-
ard in Japan and are mainly used in patients enrolled in
clinical trials. These surgeries themselves have not been
confirmed safe and feasible yet.
All patients received perioperative care according to
our ERAS program. Operations were performed by the
same team of surgeons (three specialists and four trainees).
In principle, patients with a preoperative diagnosis of
stage I disease received laparoscopic surgery with D1+
dissection, and the others received open surgery with
D2 dissection [19].ERAS program
In their Cochrane review, Spanjersberg et al. regard
ERAS protocols as programs that include 7 or more of
17 ERAS items [10]. Our ERAS program included 13
items.Preoperative
Preoperative counseling was held in the outpatient clinic
before hospitalization and in the ward after admission.
Patients could eat a normal diet until dinner of the day
before surgery. Magnesium oxide and a New Lecicarbon®
suppository (Zeria Pharmaceutical Co., Ltd., Tokyo, Japan)
were administered on the day before surgery (Table 1).Perioperative
Patients, excluding those who had gastric obstruction
with decreased output, could drink two 500-ml plastic
bottles of OS-1® (2.5% carbohydrate, Otsuka Pharma-
ceutical, Tokushima, Japan) 3 h before surgery. Pre-
medication was not administered. Anesthesia consisted
of a combination of epidural analgesia (Th 7-11) and
general anesthesia. In principle, no drain was used in
distal gastrectomy, and one or two drains were used in
total gastrectomy. The nasogastric tube was removed
immediately after surgery (Table 1).Postoperative
Day of surgery: A continuous thoracic epidural infusion of
analgesics was given for 2 days after surgery. To prevent
postoperative pain, a nonsteroidal anti-inflammatory drug
(50 mg flurbiprofen axetil) was administered intravenously
twice daily after surgery until the resumption of oral in-
take. Postoperative day (POD) 1: Patients were encour-
aged to sit out of bed for more than 6 h. POD 2: Oral
intake was started with water and a can of oral nutrition
supplement (250 ml Ensure Liquid ®, Abbott Japan Co.,
Ltd., Tokyo, Japan). After the resumption of oral intake,
300 mg of acetaminophen was administered orally three
times daily. The patients were encouraged to walk the
length of the ward. An antithrombotic agent (enoxaparin
sodium 2 000 IU twice daily or fondaparinux 2.5 mg daily)
was injected for 2 days 6 h after removal of the epidural
catheter. POD 3: The patients started to eat soft food and
were stepped up to regular food every 2 days (3 steps).
The criteria for discharge were as follows: adequate pain
relief, soft diet intake, return to preoperative mobility
level, and normal laboratory data on POD 7 (Table 1).
The ERAS program evaluated in the present study was
developed by a team of surgeons and anesthesiologists
working in close cooperation with a data safety monitor-
ing committee (DSMC). The feasibility and safety audit
was completed by the DSMC in September 2009, when
50 patients had been treated according to the ERAS pro-
gram. Our ERAS program in practice was approved both
by the institutional clinical pathway committee and the
DSMC. This study, a retrospective analysis, have been
performed upon the approval of the institutional review
board of Kanagawa Cancer Center. Informed consent for
the ERAS program and using the clinical date without
identifying personal information were taken before
surgery.
Data collection (end points)
All data were retrieved retrospectively from the patients’
database and clinical records. The primary end point
was the incidence of postoperative complications. Com-
plications were defined as ≥ grade 2 complications ac-
cording to Clavien-Dindo classification within 30 days
after surgery [20]. Secondary end points were postopera-
tive outcomes such as onset of walking, onset of oral in-
take, onset of flatus, onset of defecation, delay of meal
step-up, reoperation, postoperative hospital stay, re-
admission, and mortality. We delayed meal step-up if
the patient ate 40 percent or less of meals for 2 days.
Pathological findings were categorized according to
the 7th edition of UICC-TNM [21]. Continuous data are
expressed as medians (range).
Results
A total of 203 patients were studied.
Table 1 Time table of the modified ERAS program
Operative day -1 0 +1 +2 +3 +4 +5 +6 +7
Preoperative counseling Preoperative counseling was held in the outpatient clinic before hospitalization and in the ward after admission.
Pre-medication Patients do not receive any sedation.
Oral intake Normal diet until
midnight
Oral hydration solution
(OS-1®) 3 h before
surgery
Drink a water and oral
nutrition supplement
(Endure Liquid®)
Liquid diet (3 steps up to a
soft diet every 2 days)
Bowel preparation 1 g magnesium


















times a daily orally
→ → →
Drain and NGT No drain in distal gastrectomy,








sit out of bed
for more than
6 h
Encourage to walk the
length of the ward
→ → → → →




→ → None → →
X-ray and blood exam. ○ ○ ○ (Check
discharge
creiteria)
NGT: Nasogastric tube, ADL: Activity of daily life.
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There were 133 men and 70 women. Ten patients diagnosed
non-adenocarcinoma or having other cancer simultaneously,
sixteen patients received preoperative chemotherapy, Twenty
two patients undergoing laparoscopy-assisted total gastrec-
tomy, four patients undergoing remnant total gastrectomy,
and one patient undergoing proximal gastrectomy were ex-
cluded. The median age was 67 (32-84) years. Performance
status was good in most patients. Mean body mass index
(BMI) was 22.2 (16.2-31.4) (Table 2).
Surgical procedures
Laparoscopic surgery was performed in 76 patients (37.4%),
and total gastrectomy in 60 patients (29.6%). 83 patients
(40.9%) underwent D2 lymph node dissection. Combined
organ resection was performed in 34 patients, among
whom 29 (85.3%) additionally underwent splenectomy(including pancreatico-splenectomy in 1 patient). Bill-
roth I reconstruction was performed in 116 (57.1%) pa-
tients, and Roux-en-Y reconstruction was done in 83
(40.9%). The median operation time was 179 (80-577)
minutes. The estimated median blood loss was 110 (0-
1620) ml (Table 2).
Pathological characteristics
Early gastric cancer (T1) was confirmed in 121 patients
(59.6%). 131 patients (64.5%) had no evidence of lymph
node metastasis. Final disease stage was stage I in 128
patients (63.1%), stage II in 35 (17.2%), stage III in 31
(15.3%), and stage IV in 9 (4.4%) (Table 2).
Complications and postoperative course
Grade 2 or higher complications developed in 23 (11.3%)
patients, and grade 3 or higher complications developed
Table 2 Clinicopathological features
Patients
(N = 203)
Age (years old)* 67(32-84)
Gender Male 133 (65.5%)
Female 70 (34.5%)
BMI (kg/m2)* 22.2(16.2-31.4)
ECOG-PS 0 177 (87.2%)
1 26 (12.8%)
2 0 (0.0%)
ASA-PS I 99 (48.8%)
II 103 (50.7%)
III 1 (0.5%)




Open total gastrectomy 60 (29.6%)
Lymph node dissection D1,D1+ 120 (59.1%)
D2 83 (40.9%)
Reconstruction Billroth I 116 (57.1%)
Billroth II 4 (2.0%)
Roux-en Y 83 (40.9%)
Combined organ resection yes 34 (16.7%)
no 169 (83.3%)
Operation time (min.)* 179(80-577)
Bleeding (ml)* 110(0-1620)












BMI; Body mass index, ECOG-PS; Eastern cooperative oncology group performance




≥grade 2 n (%) ≥grade 3 n (%)
Pancreas fistula 7(3.4%) 2(1.0%)
Anastomotic leakage 3(1.5%) 3(1.5%)
Ileus 2(1.0%) 0(0%)
Anastomotic stenosis 2(1.0%) 1(0.5%)









Table 4 Postoperative outcomes
Onset of walk (POD*) 2(1-4)
Onset of oral intake (POD*) 2(1-5)
Onset of flatus (POD*) 2(0-5)
Onset of defecation (POD*) 4(2-9)
Delay of meal step up (n(%)) 10(4.9%)
Complication CD≥ grade2 (n(%)) 23(11.3%)
Reoperation (n(%)) 6(3.0%)
Postoperative hospital stay(days)* 9(7-53)
Readmission (n(%)) 4(2.0%)
Mortality (n(%)) 0(0%)
POD; Post operative day, CD; Clavien-Dindo classification, *median (range).
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(1.5%), ileus in 2 patients (1.0%), and anastomotic stenosis
in 2 patients (1.0%). The incidence of ≥ grade 2 complica-
tions in patients who underwent open distal gastrectmy,
laparoscopy-assisted distal gastrectomy, or open total gas-
trectomy were 1.9%, 3.4%, or 5.4% respectively (p = 0.069).
The incidence of ≥ grade 2 complications in patients whounderwent D1 or D1+ dissection was 5.8%, as compared
with 18.1% in patients who underwent D2 dissection (p =
0.010). The median onsets of oral intake, flatus, and
defecation were POD 2 (1-5), 2 (0-5), and 4 (2-9), respect-
ively. The step-up schedule for meals was delayed in 10
(4.9%) patients. Five of these patients (2.4%) had inad-
equate oral caloric or fluid intake because of nausea or
vomiting. Reoperation was performed in 6 (3.0%) patients.
The reasons for reoperation were leakage of the duodenal
stump in 2 patients, leakage of the gastroduodenal anasto-
mosis in 1, bowel obstruction in 1, anastomotic stenosis in
1, and pyothorax in 1. The median postoperative hospital
stay was 9 (7-53) days. 4 (2.0%) patients were readmitted
within 30 days after surgery. The reasons for readmission
were ascites, fever, poor oral intake, and surgical site infec-
tion in 1 patient each. There was no mortality. No patient
had postoperative pneumonia or required replacement of
a nasogastric tube, with exception of 3 patients who had
postoperative ileus (Tables 3 and 4).
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This is the first large study to evaluate the feasibility of a
comprehensive ERAS program in gastric surgery. In our
study, the overall incidence of morbidity (i.e., ≥grade 2
complications) was 10.8%, and the incidence of clinically
significant events (≥grade 3 complications) was only
3.9%. These results obtained with our ERAS program are
good as compared with complication rates of conventional
perioperative care group in our previous report (12.0%) as
well as other reported complication rates without ERAS
program (10.5-46.0%) [2-7,12]. Although T1 tumors and
D1 dissection were dominant in our study, the morbidity
rate in the D2 group (18.1%) was comparable to that in a
large randomized controlled trial performed in Japan
(JOCG9501 study, 20.9%) [5].
Among the many elements of ERAS programs, one of
the utmost concerns for surgeons is that early postoper-
ative feeding can induce postoperative ileus or anasto-
mosis leakage. Because of these concerns, oral intake of
food was previously not allowed for several days after
gastrectomy in Japan [22]. In some European countries,
food is also withheld for several postoperative days [23],
but this practice is not supported by adequate evidence.
In fact, in our study the incidences of postoperative ileus
and anastomotic leakage were very low (1.0% and 1.5%,
respectively), as compared with previous studies (0-
12.5% and 0-4.2%, respectively) [2-7]. The incidences of
those in conventional prieoperative care of our hospital
(0% and 2%, respectively) were similar with these results
[12]. Furthermore, meal step-up did not have to be de-
layed in nearly all patients (95.1%), and this is also simi-
lar with previous reported our internal control (96.0%)
[12]. Several studies have also demonstrated that early
oral feeding is feasible and beneficial in gastric surgery
[13-18,24,25], but this point remains controversial. Heslin
et al. reported that early enteral feeding was not beneficial
after surgery for upper gastrointestinal malignancies [26].
On the other hand, Lewis et al. found in their meta-
analysis that keeping patients ‘nil by mouth’ is without
benefit; in contrast, early enteral feeding was suggested to
reduce mortality [27]. There were six complications that
need reoperation in current study. Among those, possibil-
ity of relation between the leakage of the gastroduodenal
anastomosis and ERAS program could not be denied. But
others seem to be unlikely. Our results and the findings of
previous studies suggest that early oral or enteral feeding
is at least feasible and does not increase the risk of postop-
erative ileus or anastomotic leakage.
Our study had several limitations. 1) It was conducted
retrospectively in a single hospital, and the analyses and
endpoints were not preplanned. 2) Most patients had
good performance status. Patients with poor performance
status (e.g. Eastern cooperative oncology group perform-
ance status ≥3, severe dementia, and swallowing difficulty)could not be treated in our hospital, because we specialize
in cancer treatment. These could be selection bias. 3) More
than half of the patients had T1 disease and underwent
limited lymph node dissection (D1+), whichmight account
for the good results of our study. In particular, D2 or more
radical lymph node dissection has been repeatedly reported
to increase the risk of surgery-related complications [2-5].
Consistent with the previous findings, the incidence of
complications was higher after D2 dissection than after
D1 dissection in our study. Finally, 4) our ERAS pro-
gram did not include fluid management, which is one
of the key elements of ERAS programs. There was not
robust evidence of perioperative fluid management in
gastric surgery at the time we introduced ERAS.
Conclusions
In conclusion, our results suggest that our ERAS pro-
gram is feasible in at least early-staged and relatively
young patients undergoing elective gastric surgery. Fur-
ther studies, for which population ERAS program can be
applied and whether ERAS programs have potential ben-
efits, are necessary.
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